Trending News on Targeted Oncology, Week of October 23, 2020

October 23, 2020
Danielle Ternyila
Danielle Ternyila

Targeted Oncology reviews trending news online for the week of October 23, 2020, including updates in oncology and the COVID-19 pandemic.

This week, the FDA granted a Priority Review designation for the treatment of advanced renal cell carcinoma to a potential combination regimen. Another FDA Priority Review was granted for an EGFR tyrosine kinase inhibitor for the treatment of early-stage EGFR-mutant non–small cell lung cancer (NSCLC).

The FDA also granted a Fast Track designation to a potential combination for the treatment of chronic lymphocytic leukemia.

Check out all our coverage from the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat.

These updates and others were trending:

FDA-Approved Frontline Agent for Metastatic NSCLC May Be Effective as Second-Line Treatment of Adenocarcinoma of the Lung

Afatinib (Gilotrif), an FDA-approved frontline treatment for patients with metastatic NSCLC, has now demonstrated efficacy and tolerable safety in the second-line setting of metastatic squamous cell carcinoma of the lung, especially with the addition of pembrolizumab (Keytruda) in the frontline setting, according to new real-world data presented during the International Association for the Study of Lung Cancer 2020 North America Conference on Lung Cancer.

Real-World Data Support Use of Multikinase Inhibitors in Differentiated Thyroid Cancer

In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

Treatment Options for HER2+ Breast Cancer Open to Multiple Lines of Therapy and Subgroups

Until recently, few options existed for patients with HER2-positive breast cancer who progressed on earlier lines of therapy. Recent approvals of 3 drug combinations offer new tools that may prolong life and control brain metastases across lines of therapy, according to Rashmi K. Murthy, MD, MBE.

Non-Chemotherapy Regimen Induces Encouraging Responses in Advanced EGFR-Mutant NSCLC

In an interview with Targeted Oncology, Alexander Spira, MD, PhD, discussed the findings from the clinical trial evaluating amivantamab in combination with lazertinib as treatment of patients with advanced EGFR-mutant NSCLC.

Health-Related QoL Data Stand Out in Support of Nivolumab Plus Cabozantinib in Advanced RCC

In an interview with Targeted Oncology, Bradley McGregor, MD, discussed the findings from the CheckMate-9ER study of nivolumab (Opdivo) and cabozantinib (Cabometyx) as treatment of patients with advanced renal cell carcinoma, as well as the health-related quality of life data supporting the use of this combination.

FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS Landscape

Guillermo Garcia-Manero, MD, discusses how the recently approved combination regimen of decitabine and cedazuridine fits into the treatment landscape for patients with myelodysplastic syndromes.

Exploring the Reasons Why Certain Prostate Cancers Are More Aggressive

Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.

Special Feature: COVID-19

Guidelines for MCL Set to Change Due to COVID-19

Guidelines are available to help summarize the best treatment for patients with mantle cell lymphoma (MCL) across various stages based on the greatest level of evidence available and the most up-to-date data, but the landscape has completed changes recently due to COVID-19, according to Robert Marcus, MA, FRCP, FRCPath.